MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202617074778 A) filed by Trustees Of The University Of Pennsylvania on June 17, 2026, for Sustained Delivery Of Nitrile-Containing Jak Inhibitors From A Hydrogel Through Reversible Thioimidate Adducts.
Inventors include Wang, Leo; and Cotsarelis, George.
The application for the patent was published on July 31, 2026, under issue no. 31/2026.
Abstract: The invention provides sustained delivery JAK inhibitor hydrogels for treatment of an inflammatory disorder, autoimmune disease, an autoimmune and inflammatory hair loss, and/or a non-inflammatory disorder hair loss, the JAK inhibitor hydrogel comprising a JAK inhibitor having a nitrile group reversibly conjugated to a thiol group of a thiolated polymer to form a thioimidate adduct. The invention also provides injectable pharmaceutical compositions for treatment of an inflammatory disorder, an autoimmune disease, an autoimmune and inflammatory hair loss, and/or a non-inflammatory disorder hair loss, the injectable pharmaceutical compositions comprising a nitrile-containing JAK inhibitor and a pharmaceutically acceptable carrier.
Disclaimer: Curated by HT Syndication.
